TORONTO, March 27, 2026 (GLOBE NEWSWIRE) — Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) (“Electra” or the “Company”) today reported 2025 financial results, highlighting a successful recapitalization and restart of construction of its cobalt sulfate refinery. HighlightsBoard approved US$73 million construction budget to complete the refinery Strengthened balance sheet, through recapitalization, including significant debt conversion to equity Reactivated full-scale construction in November following recapitalization Completed early works and advanced major construction tendering to support disciplined execution Initiated domestic feedstock testing to build a pipeline for North American supply Completed feasibility-level engineering study for a modular battery recycling facility Strengthened Board with deep expertise...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, March 27, 2026 (GLOBE NEWSWIRE) — Helios Fairfax Partners Corporation (TSX: HFPC.U) today announced its financial results for the fourth quarter and year ended December 31, 2025. All dollar amounts in this news release are expressed in U.S. dollars except as otherwise noted. Management Commentary “2025 delivered the strongest net earnings and highest gains in our portfolio that Helios Fairfax Partners has achieved since it was established in 2020. Record net earnings of $41 million were driven by meaningful growth in book value and reflect the strong performance of our Helios Managed Investments,” said Tope Lawani and Babatunde Soyoye, Co‑CEOs of Helios Fairfax Partners. “HFP is invested in a diversified set of strategies, funds and...

SPRINGFIELD, Mo., March 27, 2026 (GLOBE NEWSWIRE) — Paul Mueller Company (OTC: MUEL) today announced earnings for the fourth quarter ended December 31, 2025.CONSOLIDATED STATEMENTS OF INCOME                     Three Months Ended   Twelve Months Ended    December 31   December 31      2025       2024       2025       2024                   Net Sales   $ 94,142     $ 70,474     $ 287,001     $ 248,585  Cost of Sales     62,054       44,665       193,201       166,124  Gross Profit   $ 32,088     $ 25,809     $ 93,800     $ 82,461  Selling, General and Administrative Expense     15,100       12,235       50,263       46,248  Operating Income   $ 16,988     $ 13,574     $ 43,537     $ 36,213  Interest Expense     (47 )     (45 )     (210 )     (301 )Other Income     948       492       2,473       2,377  Income...

GREAT NECK, N.Y., March 27, 2026 (GLOBE NEWSWIRE) — Manhattan Bridge Capital, Inc. (Nasdaq: LOAN) (the “Company”) announced today that net income for the year ended December 31, 2025 was approximately $5,111,000, or $0.45 per share (based on approximately 11.4 million weighted-average outstanding common shares), versus approximately $5,591,000, or $0.49 per share (based on approximately 11.4 million weighted-average outstanding common shares) for the year ended December 31, 2024, a decrease of approximately $480,000, or 8.6%. This decrease was primarily due to lower interest income, partially offset by lower interest expense. Total revenue for the year ended December 31, 2025, was approximately $8,666,000, compared to approximately $9,689,000 for the year ended December 31, 2024, a decrease of $1,023,000, or 10.6%. The decrease...

Announced partnership with Australian CRO to accelerate initiation of CLD-401 clinical trial The Company has received feedback from the FDA through Type D interactions, and the Company believes its manufacturing and analytical approaches for CLD-401 are in alignment with FDA guidance; Calidi expects to file an IND by end of 2026 Partnered with Matica Bio around the GMP manufacturing of CLD-401 Presented new data on in situ T-cell engagers (TCEs) at 2026 AACR-IO conference Raised $6.5 million in public offering and ATM salesSAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today reported its fourth quarter and full-year 2025 operating and financial results and reviewed recent...

NEW YORK and TORONTO, March 27, 2026 (GLOBE NEWSWIRE) — iAnthus Capital Holdings, Inc. (“iAnthus” or the “Company”) (CSE: IAN, OTCID: ITHUF), which owns, operates, and partners with regulated cannabis operations across the United States, today reported its financial results for the fourth quarter and year ended December 31, 2025. The Company’s Annual Report on Form 10-K (the “Annual Report”), which includes its audited consolidated financial statements for the year ended December 31, 2025 and the related management’s discussion and analysis of financial condition and results of operations, can be accessed on the Securities and Exchange Commission’s (“SEC’s”) website at www.sec.gov, on the System for Electronic Document Analysis and Retrieval’s (SEDAR+) website at www.sedarplus.com, and on the Company’s website at www.iAnthus.com....

EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – FDA Type A endpoint alignment in July 2025, Phase 3 protocol submitted to the FDA with comments expected in early Q2 2026 EB612, the first long-acting oral PTH peptide replacement tablet for patients with hypoparathyroidism – final variants selected, pre-IND initiatives underway with intention to file IND in late 2026 in partnership with OPKO EB618, the first Oral OXM (GLP-1/Glucagon) peptide tablet for patients with metabolic syndromes – PK/PD validation complete, intention to file IND pursuant to OPKO Phase 1 SAD/MAD SC injection data TEL AVIV, March 27, 2026 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today reported...

Orlando, Fla., March 27, 2026 (GLOBE NEWSWIRE) — CNL Strategic Capital, LLC (CNL Strategic Capital or the Company) seeks to provide current income and long-term appreciation to investors by acquiring controlling equity stakes in combination with loan positions in privately owned middle-market businesses. The Company announced its operating results for the year ended Dec. 31, 2025. Highlights:As of Dec. 31, 2025, CNL Strategic Capital’s portfolio consisted of equity and debt investments in 18 portfolio companies and had approximately $1.5 billion in total assets, compared with approximately $1.3 billion as of Dec. 31, 2024. For the year ended Dec. 31, 2025, the Company recognized a net change in unrealized appreciation on investments of approximately $113.6 million, including unrealized foreign currency gain and had total investment...

WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the fourth quarter and full-year 2025 financial results and provided a summary of recent developments. “2025 was a productive year for Monopar, marked by multiple ALXN1840 data presentations, an important publication, a strengthened balance sheet and continued progress toward a planned New Drug Application submission for ALXN1840 in Wilson disease,” said Chandler Robinson, MD, Chief Executive Officer of Monopar. “We also recently strengthened our leadership team with the addition of Susan Rodriguez as Chief Commercial and Strategy Officer as we prepare for the potential launch...

According to the current regulations, Sword Group announces that its 2025 Financial Report has been made available to the public.It was sent to the Commission de Surveillance du Secteur Financier (CSSF) and was also filed with the Luxembourg Stock Exchange.It can be viewed and downloaded on the website of the company: 2025 FINANCIAL REPORT About Sword GroupSword has 3,600+ IT/Digital specialists active in 50+ countries to accompany you in the growth of your organisation in the digital age.As a leader in technological and digital transformation, Sword has a solid reputation in complex IT & business project management.Sword optimises your processes and enhances your data.AttachmentSwordGroup_Availability of the 2025 Financial Report_V27032026